text_1: FDA advisory panel rejects J&J drug for acute coronary syndrome.
text_2: Johnson & Johnson’s anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.